30 closest matches · ranked by relevance
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Cushings Disease · Cushing Disease
Primary: Percentage of Responders to LCI699 Based on the Change in Mean Urinary Free Cortisol (UFC) From Baseline to Week 10 — 100.0 Percentage of participants
Cushings Disease
Primary: Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and Strata — 86.1; 29.4 Percentage of participants — p=<.001
Cushing's Disease
Primary: Percentage of Randomized Participants With a Complete Response — 37; 2 Participants — p=<.0001
Cushing's Syndrome
Primary: Effectiveness of Osilodrostat — 23 Participants
Cushing Syndrome · Cushing Disease
Primary: Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN) — 0; 1; 50; 26 Participants
Cushings Disease
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability Profile of Pasireotide s.c. — 11; 13; 34; 54 Participants
Cushing's Disease · Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 4 participants
Cushing's Disease
Primary: Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE) — 53.1; 53.1; 29.1; 27.3 percentage of…
Cushing's Syndrome
Primary: Improvement in Diabetes and/or Glucose Intolerance. — 15 participants
Cushing's Disease
Primary: Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration — 41.9; 40.8 percentage of participants
Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 30 participants
Cushing's Syndrome · Ectopic Corticotropin Syndrome · Adrenal Adenoma
Primary: Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 — -99.0; -97.8; -94.5; -91.5 percentage change
Cushing's Disease
Primary: Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group — 12; 21 Responders
Cushing's Disease · Acromegaly
Primary: Change in HbA1c From Randomization to Approximately 16 Weeks — -0.12; 0.26; 0.33; 0.45 Hba1c percentage
Endogenous Cushing's Syndrome
Primary: Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic…
Cushing Syndrome
Primary: Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase. — 3; 1; 1; 1 Participants — p=0.0215
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Cushing's Syndrome
Primary: Number of Participants With Adverse/Serious Adverse Events — 115; 50; 34; 3 Participants
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
Adrenal Insufficiency
Primary: Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs — 0.8; 0.86; 0.93; 0.92 correlation coefficient
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…